Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ('Shuttle Pharma' or the 'Company'), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities.
'I am excited to welcome Christopher Cooper as Co-CEO of Shuttle Pharma,' commented Dr. Anatoly Dritschilo, Chairman of the Board and CEO of Shuttle Pharma. 'Christopher brings a wealth of business acumen which when balanced with the inherent scientific expertise of the entire Shuttle Pharma team should allow for a highly effective executive structure that should inspire confidence going forward. I believe this appointment will enhance decision-making, supports fundraising, and prepares us for the accelerated achievement of key milestones in the future.'
Christopher Cooper added, 'I am enthusiastic to join the incredibly talented team at Shuttle Pharma as we aim to improve the lives of millions impacted by cancer and bring hope to patients and families around the world. The Co-CEO structure will allow for parallel execution of R&D, regulatory and general business operations. I look forward to leveraging my business experience to allow Dr. Dritschilo to focus more of his efforts going forward on the successful execution of the Company's ongoing key Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma and continued advancement of the Diagnostics subsidiary.'
Mr. Cooper has more than 27 years of experience in management and finance, having worked in the oil and gas, telecommunications and technology industries. In addition to his appointment as Interim Co-CEO of the Shuttle Pharma, Mr. Cooper also serves as President, CEO and Founder of First Towers & Fiber Corp., a telecommunications infrastructure company with operations in Latin America, positions he has held since 2017. From 2010 until 2017, Mr. Cooper served as President and CEO of Aroway Energy, Inc., a Vancouver, British Columbia-based oil and gas company, where he was responsible for overseeing day to day operations, financial reporting, and oversaw acquisitions and debt and equity financing. From 1998 until 2010, Mr. Cooper served as a Corporate Consultant to various companies in the technology and resources sectors, oversaw restricting activities for several distressed public companies, and was responsible for raising more than $100 million in debt and equity for his clients. Mr. Cooper received his MBA from Dowling College in 1995 and his BBA in Business Administration from Hofstra University.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 24, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle PharmaceuticalsAnatoly Dritschilo, M.D., Co-CEO240-403-4212info@shuttlepharma.com
Investor ContactsLytham Partners, LLCRobert Blum602-889-9700shph@lythampartners.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Why Investors Are Turning to Freshworks (FRSH) for AI Exposure
Freshworks Inc. (NASDAQ:FRSH) is one of the . On August 11, Oppenheimer analyst Brian Schwartz reiterated an Outperform rating on the stock with a $19.00 price target. The rating affirmation follows a webinar and investor meetings with the company's CFO. Oppenheimer hosted Freshworks CFO Tyler Sloat at its 28th Annual Technology, Internet, and Communications Conference on Monday. The conference included discussions about the company's market aopportunities, artificial intelligence momentum, and competitive positioning. The firm recommends Freshworks to those investors who are looking for exposure to artificial intelligence. 'We hosted a well-attended webinar and investor meetings with Tyler Sloat, CFO of Freshworks, at our 28th Annual Technology, Internet, and Communications Conference earlier today. Management's tone was upbeat as the discussion centered on the company's large and underpenetrated TAM, AI business momentum, growth opportunities and competitive moat in the AI era, its go-to-market strategy with improving efficiency, move into adjacent workflow markets, multi-products adoption, product led growth momentum, stabilization in the CX business, technology updates, and productivity trends." An experienced portfolio manager delivering a presentation to a group of investors. "Following the webinar, we remain positive on Freshworks' business momentum and AI monetization trajectory. Bottom Line: We recommend FRSH for investors looking for exposure to AI, the services modernization and customer/IT engagement themes at a discount valuation versus peers.' Freshworks Inc. is a software development company that provides software-as-a-service products. While we acknowledge the potential of FRSH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
a few seconds ago
- Yahoo
Why Analysts Remain Cautious on CoreWeave (CRWV) Despite Strong Growth
CoreWeave, Inc. (NASDAQ:CRWV) is one of the Must-Watch AI Stocks on Wall Street. On August 13, Citizens JMP analyst Greg Miller reiterated a Market Perform rating on the stock without a price target. The rating affirmation reflects CoreWeave's stronger-than-expected results and positively revised outlook. JMP has noted how CoreWeave encompasses a business model that enables cloud and hyperscale companies to manage capital expenditure increases while accelerating time to market for their services. At the same time, it remains cautious about GPU-as-a-Service providers' ability to steer through falling average selling prices and increasing customer churn against rising real estate costs. A financial analyst evaluating the large- and mid-cap U.S. equity market on a digital display. 'CoreWeave reported 2Q25 results that one would expect after such a high-profile IPO; stronger-than-consensus expectations with a positively revised outlook that clearly demonstrates the hyperscale company's willingness to push balance sheet liabilities onto other companies in exchange for a high initial margin (over a 3-4-year term). While we continue to believe cloud/hyperscale companies will accelerate the push to use these companies to help manage capex increases and speed time to market, we remain cautious with regard to GPUaaS providers' abilities to manage a declining ASP and increasing churn against the backdrop of an increasing real estate cost structure. We remain Market Perform rated on CoreWeave, as we wait for investors to gain a better understanding of the underlying KPIs.' CoreWeave, Inc. (NASDAQ:CRWV) is a cloud platform provider that provides equipment for AI and other computing purposes. While we acknowledge the potential of CRWV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
a few seconds ago
- Yahoo
Prediction: Nvidia's New China Deal Will Be a Game-Changer. Here's Why
Key Points While most of Nvidia's revenue hails from the U.S. and Europe, the Chinese market represents an estimated $50 billion opportunity. Recent changes to tariff policies and export controls have stifled Nvidia's potential in China throughout 2025. Nvidia and the U.S. government have formed a deal structure that helps pave the way for Nvidia to reclaim dominance in the key Asian market. 10 stocks we like better than Nvidia › Although it's only August, 2025 has already played out like a modern-day Greek tragedy for semiconductor powerhouse Nvidia (NASDAQ: NVDA). Its year has been marked by a litany of setbacks, comebacks, and everything in between. Earlier this year, more than $1 trillion of Nvidia's market value was wiped out. Yet today, the company boasts a market cap of $4.4 trillion -- reclaiming the crown as the most valuable company in the world. At the center of Nvidia's headaches in 2025 is China -- and no, not because of DeepSeek. The real culprit has been a wave of sweeping tariff policies and export controls that have curtailed Nvidia's influence in the Chinese AI market. Now, after months of negotiations with regulators in Washington, it appears that the tide may be turning. Nvidia could be on the precipice of reestablishing its presence in one of its most crucial Asian markets. Let's unpack the details of Nvidia's new deal structure in China and examine why it should be celebrated as a massive win for investors. How big an opportunity is China for Nvidia? According to accounting and consulting firm Deloitte, the global total addressable market (TAM) for semiconductors, as measured by sales, reached $627 billion in 2024. Deloitte projects that the market will grow at a compound annual growth rate (CAGR) of 19% over the coming decades -- ultimately reaching $2 trillion by 2040. Outside of the U.S., China remains one of the most important markets fueling demand for high-performance chipsets, particularly graphics processing units (GPUs). Nvidia CEO Jensen Huang has estimated that the AI opportunity in China alone could be worth as much as $50 billion. In 2024, Nvidia generated $130 billion in revenue, with China capturing roughly 13% of this sum. During the first quarter of 2025, Nvidia's $5.5 billion of China sales accounted for roughly 12.5% of total revenue. This leveling trend underscores how the current administration's policies toward China have started to constrain Nvidia's growth potential in the region. Why is Nvidia's new China deal so important? According to multiple news outlets, Nvidia has reached an agreement with Washington regarding its operation in China. Under the terms, Nvidia will pay 15% of its China-based sales to the U.S. government. In effect, the arrangement provides Nvidia with a pathway to penetrate this critical market through its tailored H20 chips. While this might initially resemble a tax, investors should avoid viewing it through that lens. First, the agreement applies to sales of Nvidia's AI chips rather than to profits, unlike traditional forms of taxation. Moreover, the 15% rate does not appear to be variable in structure like a royalty, which is typically tied to intellectual property (IP) and subject to fluctuate. While this deal might appear unusual at first glance, these structures are not without precedent in global business practices. For example, energy companies that extract natural resources or commodities in foreign countries often operate under similar revenue-sharing agreements with host nations in exchange for distribution rights. In my view, dedicating a modest share of sales to secure access to China represents a strategic trade-off. In the long run, it allows Nvidia to preserve its dominant position in one of the world's most important AI markets and prevents domestic rivals such as Huawei from eroding its competitive moat. Is Nvidia stock a buy? While Nvidia's forward price-to-earnings (P/E) ratio has been expanding recently, levels remain muted compared to peaks reached previously during the AI revolution. In my view, part of this multiple compression reflects concerns surrounding China -- perhaps overly so. Nvidia's new agreement in Washington offers the company renewed momentum, securing revenue in a critical market without forfeiting much in the way of profits -- even with the 15% remittance to the U.S. government. Over the long term, I see this arrangement as a strategic mechanism for Nvidia to strengthen its position overseas and deliver durable growth across the global AI infrastructure market. As these fundamentals take hold, I think the company's valuation multiples could expand further, potentially driving the stock to new highs sooner than many investors may be expecting. For that reason, I see Nvidia stock as a no-brainer opportunity to buy hand over fist right now and hold for years to come. Do the experts think Nvidia is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nvidia make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,070% vs. just 184% for the S&P — that is beating the market by 885.55%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Adam Spatacco has positions in Nvidia. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Prediction: Nvidia's New China Deal Will Be a Game-Changer. Here's Why was originally published by The Motley Fool Sign in to access your portfolio
